Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis

American Journal of Kidney Diseases

Volumn 46, Issue 4, 2005, Pages 713-719

  Wong, Teresa Yuk Hwa ^a,b   Szeto, Cheuk Chun ^a   Chow, Kai Ming ^a   Leung, Chi Bong ^a   Lam, Christopher Wai Kei ^a   Li, Philip Kam Tao ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Union Hospital   (Hong Kong)

Author keywords

Diabetes; Dialysis; Inflammatory markers; Insulin requirement; Rosiglitazone

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; ROSIGLITAZONE;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADD ON THERAPY; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; HYPOLIPOPROTEINEMIA; INSULIN SENSITIVITY; INSULIN TREATMENT; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PERITONEAL DIALYSIS; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RASH; REGRESSION ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

AGED; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; THIAZOLIDINEDIONES; UREMIA; WEIGHT GAIN;

EID: 25644457679     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2005.06.020     Document Type: Article

References (36)

1. B.M. Spiegelman PPAR Adipogenic regulator and thiazolidinedione receptor Diabetes 47 1998 507 514
2. M.C. Cranberry, E.F. Schneider, V.A. Fonseca The role of troglitazone in treating the insulin resistance syndrome Pharmacotherapy 18 1998 973 987
3. D.G. Maggs, T.A. Buchanan, C.F. Burant, G. Cline, B. Gumbiner, W.A. Hsueh Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, doubled-blind, placebo-controlled trial Ann Intern Med 128 1998 176 185
4. S. Schwartz, P. Raskin, V. Fonseca, J.F. Graveline Effect of troglitazone in insulin treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group N Engl J Med 338 1998 861 866
5. P. Raskin, M. Rendell, M.C. Riddle, J.F. Dole, M.I. Freed, J. Rosenstock Rosiglitazone Clinical Trials Study Group A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes Diabetes Care 24 2001 1226 1232
6. D.T. Finegood, M.D. McArthur, D. Kojwang Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death Diabetes 50 2001 1021 1029
7. S.J. Baldwin, S.E. Clarke, R.J. Chenery Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone Br J Clin Pharmacol 48 1999 424 432
8. M.J. Lenhard, W.B. Funk Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis Diabetes Care 24 2001 168 169
9. P. Raskin, E.B. Rappaport, S.T. Cole, Y. Yan, R. Patwardhan, M.I. Freed Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes Diabetologia 43 2000 278 284
10. K. Thompson-Culkin, B. Zussman, A.K. Miller, M.I. Freed Pharmacokinetics of rosiglitazone in patients with end-stage renal disease J Int Med Res 30 2002 391 399
11. B.J. Goldstein Rosiglitazone Int J Clin Pract 54 2000 333 337
12. Z. Chen, S. Ishibashi, S. Perrey Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice Pleiotropic effects on CD36 expression and HDL Arterioscler Thromb Vasc Biol 21 2001 372 377
13. W.A. Hsueh, S. Jackson, R.E. Law Control of vascular cell proliferation and migration by PPAR-gamma A new approach to the macrovascular complications of diabetes Diabetes Care 24 2001 392 397
14. M.J. Blumenkrantz Nutrition J.T. Daugirdas T.S. Ing Handbook of Dialysis ed 2 1994 Little Brown Boston, MA 383 chap 22
15. A.H. Tzamaloukas, M.C. Saddler, G.H. Murata Symptomatic fluid retention in patients on continuous peritoneal dialysis J Am Soc Nephrol 6 1995 198 206
16. M.S. Wu, C.C. Yu, C.W. Yang Poor pre-dialysis glycemic control is a predictor of mortality in type II diabetic patients on maintenance hemodialysis Nephrol Dial Transplant 12 1997 2105 2110
17. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
18. P. Passadakis, E. Thodis, V. Vargemezis, G. Oreopoulos Recommendations for glucose control in diabetics on CAPD Int J Artif Organs 22 1999 657 664
19. D. Smith, R.A. DeFronzo Insulin resistance in uremia mediated by post binding defects Kidney Int 22 1982 54 62
20. T.Y. Wong, J.C.N. Chan, C.C. Szeto, C.B. Leung, P.K. Li Clinical and biochemical characteristics of type 2 diabetic patients with end stage renal failure on continuous ambulatory peritoneal dialysis-Relationships with insulin requirement Am J Kidney Dis 34 1999 514 520
21. A.P. Rocchini, C. Moorehead, S. DeRemer, T.L. Goodfriend, D.L. Ball Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II Hypertension 15 1990 861 866
22. R.J. Sigal, M. El-Hashimy, B.C. Martin, J.S. Soeldner, A.S. Krolewski, J.H. Warram Acute postchallenge hyperinsulinemia predicts weight gain A prospective study Diabetes 46 1997 1025 1029
23. R.N. Foley, P.S. Parfrey, M.J. Sarnak Clinical epidemiology of cardiovascular disease in chronic renal failure Am J Kidney Dis 32 suppl 5 1998 S112 S119
24. P. Libby, P.M. Ridker, A. Maseri Inflammation and atherosclerosis Circulation 105 2002 1135 1143
25. M. Espinoza, A. Aguilera, M. Auxiliadora Bajo Tumor necrosis factor alpha as a uremic toxin Correlation with neuropathy, left ventricular hypertrophy, anemia and hypertriglyceridemia in peritoneal dialysis patients Adv Perit Dial 15 1999 82 86
26. V. Panichi, M. Migliori, S. De Pietro C-Reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure Nephron 91 2002 594 600
27. P. Stenvinkel, O. Heimburger, F. Paultre Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure Kidney Int 55 1999 1899 1911
28. G. Haraguchi, Y. Kobayashi, M.L. Brown PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage poB-48 receptor J Lipid Res 44 2003 1224 1231
29. V. Pasceri, H.D. Wu, J.T. Willerson, E.T. Yeh Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators Circulation 101 2000 235 238
30. C. Jiang, A.T. Ting, B. Seed PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 291 1998 82 86
31. T.L. Yue, J. Chen, W. Bao In vivo myocardial protection from ischemia/reperfusion injury by the PPAR agonist rosiglitazone Circulation 104 2001 2588 2594
32. M. Ricote, A.C. Li, T.W. Willlson, C.J. Kelly, C.K. Glass The PPAR is a negative regulator of macrophage activation Nature 391 1998 79 82
33. S.M. Haffner, A.S. Greenberg, W.M. Weston, H. Chen, K. Williams, M.I. Freed Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus Circulation 106 2002 679 684
34. M.C. Chapelsky, K. Thompson-Culkin, A.K. Miller, M. Sack, R. Blum, M.I. Freed Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency J Clin Pharmacol 43 2003 252 259
35. P. Haban, R. Simoncic, E. Zidekova, L. Ozdin Role of fasting serum C-peptide as a predictor of cardiovascular risk associated with the metabolic X-syndrome Med Sci Monit 8 2002 CR175 CR179
36. R.W. Nesto, D. Bell, R.O. Bonow Thiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the AHA and ADA Circulation 108 2003 2941 2948